Prof Boissel speaks with ec
ancer about results from the GRAALL-2005 study, which assessed the response of adolescent and young adult patients to HSCT and consolidation therapy.
He identifies Ph-like and ABL-like subgroup of patient genotypes which indicate a sensitivity to TKI therapy, and considers the case of a patient who, initially unresponsive to prednisone, responded well to blinatumomab and dasatinib therapy before stem cell transplant, and is now in remission.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.